Podcasts about Biomanufacturing

Edward Shenderovich is the Founder and CEO of Roebling, a software platform that helps industrial companies evaluate, design, and finance manufacturing projects before breaking ground. After initially setting out to solve bottlenecks in biomanufacturing, Shenderovich and his team uncovered a broader challenge: the economics of scaling physical infrastructure are often poorly understood until it's too late. In this episode of Inevitable, Cody and Edward explore whether the US is making the same mistake with domestic manufacturing that climate tech once made with the “green premium.” If consumers were unwilling to pay more for cleaner products, will they pay more for American-made ones? The conversation examines China's long-term manufacturing strategy, the gap between scientific breakthroughs and industrial scale-up, and why engineering—not invention—is often the missing link in commercial success. Edward argues that national security, data sovereignty, and AI infrastructure may become the forces that justify renewed domestic investment in manufacturing and energy systems. They also discuss the lessons learned from the recent biomanufacturing boom and bust, why many bioindustrial companies struggled to achieve economic viability, and how AI can help bridge the gap between R&D and large-scale industrial deployment. Finally, Edward shares how Roebling is using AI-powered techno-economic analysis to help companies build factories that can actually compete on cost and performance. Episode recorded on May 28, 2026 (Published on June 9, 2026). In this episode, we cover:  (0:00) An overview of Roebling  (3:37) Why consumers rarely pay more for domestic or sustainable products  (6:12) How the US can compete with China's manufacturing strategy  (7:25) The gap between R&D innovation and industrial scale-up  (9:13) Why engineering is often the bottleneck  (11:25) AI data centers as a catalyst for industrial and energy infrastructure  (14:30) National security, data sovereignty, and domestic manufacturing  (17:31) Roebling's origins in biomanufacturing  (20:03) Why AI may finally help unlock biology at scale  (23:25) Building products that are better, not just greener  (26:11) How Roebling helps companies plan and finance factories  (31:08) Lessons from the biomanufacturing boom and bio-winter  (34:33) The opportunities of nuclear energy and industrial growth  Enjoyed this episode? Please leave us a review! Share feedback or suggest future topics and guests at info@mcj.vc.Connect with MCJ:Cody Simms on LinkedInVisit mcj.vcSubscribe to the MCJ Newsletter*Editing and post-production work for this episode was provided by The Podcast Consultant

Send us Fan MailExoZymes (NASDAQ: EXOZ) CEO Michael Heltzen joins Tim Gerdeman and Robert Sassoon in this episode of the WTR Small-Cap Spotlight podcast to discuss the company's AI-driven, cell-free biomanufacturing platform and how it aims to overcome longstanding scalability challenges in synthetic biology. The conversation covers the scientific differentiation of its “exozyme” enzyme engineering approach, the commercial strategy behind its lead programs in metabolic health (NCT) and non-intoxicating cannabinoids, and the broader opportunity to produce high-value molecules that have historically been inaccessible at scale. The podcast also explores regulatory dynamics, near-term commercialization milestones, and ExoZymes' dual strategy of advancing internal assets while positioning the platform for future licensing, alongside considerations around capital efficiency and funding.

The National Laboratory of the Rockies' podcast is back with a new name and brand! In our first episode as Peaks to Power, you'll hear about: A rooftop “sunscreen” that's keeping buildings cool in summer while protecting roofs from ultraviolet sunrays  A bioplastic made from hemp seed oil that might one day be found in aerospace, automotive, battery, and construction materials  A new approach, called cell-free biomanufacturing, that NLR is pioneering to turn biomass and waste into useful chemicals. This episode was hosted by Kerrin Jeromin and Taylor Mankle, written and produced by Allison Montroy, Hannah Halusker, and Kaitlyn Stottler, and edited by Taylor Mankle, Joe DelNero, and Brittany Falch. Graphics are by Brittnee Gayet. Our title music is written and performed by Ted Vaca and episode music by Chuck Kurnik, Jim Riley, and Mark Sanseverino of Drift BC. Peaks to Power is created by the U.S. Department of Energy's National Laboratory of the Rockies in Golden, Colorado. Email us at podcast@nlr.gov. Follow NLR on X, Instagram, LinkedIn, YouTube, Threads, and Facebook.  

Episode: 3369 Small cells and microorganism that behave like living factories.  Today, tiny living factories.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore China's burgeoning role in the synthetic biology sector, as outlined in a recent article discussing China's strategic focus on biotechnology within its latest five-year plan. This strategy identifies biomanufacturing, particularly synthetic biology and genetic engineering, as pivotal for China's emerging bioeconomy. The nation's approach frames biology as a transformative industrial platform poised to reshape pharmaceuticals, materials science, agriculture, and energy industries. Central to this transformation is DNA synthesis, which allows for the design and manufacture of genetic sequences. As China rapidly expands its synthetic biology capabilities, questions arise about its potential to become an innovation powerhouse, the competitiveness of Chinese firms in DNA synthesis, and geopolitical factors affecting international cooperation and supply chains. Insights from industry leaders highlight China's unique industrialization strengths. The country excels in rapidly scaling technologies due to its ability to mobilize capital, infrastructure, and manufacturing swiftly—a capability that surpasses Europe and the U.S. This aligns with China's national biomanufacturing strategy aimed at developing vast production systems across pharmaceuticals and industrial biotechnology. Beyond sheer manufacturing capacity, China is constructing a comprehensive ecosystem to bolster advanced biotechnology. The nation's development of clinical infrastructure and pharmaceutical manufacturing is noteworthy. China is actively exploring personalized therapies and building regulatory pathways for advanced treatments, signaling a potential shift in global biotech dynamics. Domestically, Chinese companies are developing technology platforms to reduce dependence on imported equipment and Western supply chains. The competitive landscape in DNA synthesis is evolving beyond traditional commodity-versus-innovation narratives, as both Chinese and Western companies pursue similar technological advancements. However, geopolitical tensions complicate collaborations between Chinese and Western firms. Export controls highlight the growing barriers to cooperation. Despite price competitiveness from Chinese DNA synthesis providers, concerns over data security and regulatory risks are prompting some Western buyers to favor suppliers from Europe or the US. Shifting gears to regulatory matters, recent developments highlight a dynamic industry characterized by scientific advancements, regulatory shifts, legal battles, and strategic corporate maneuvers. Central to these is the call for enhanced transparency and evidence standards in the FDA's accelerated approval pathway. Strengthening evidence requirements aims to ensure that drugs approved under this pathway are supported by robust scientific data, ultimately safeguarding patient health and maintaining public trust in regulatory institutions. A landmark financial event has unfolded with Kailera Therapeutics' record-breaking IPO, raising $625 million to bolster its obesity treatment pipeline. This significant capital inflow not only sets a new benchmark for biotech IPOs but also underscores burgeoning interest in addressing obesity—an area with substantial unmet medical needs. In legal arenas, Teva Pharmaceuticals scored a victory as an appeals court revived a $177 million verdict against Eli Lilly concerning patent disputes over migraine medications. Additionally, Viatris and Teva have initiated recalls due to issues with drug dissolution and raw material approvals. The appointment of Dr. Erica Schwartz as the potential Director of the CDC marks another pivotal moment. Her leadership could steer the CDC towards more effective public health responses. On a broader industry scale, there is anSupport the show

The $127 million federal investment signifies a targeted effort by the Government of Canada to strengthen the Canadian biomanufacturing and life sciences ecosystem. Specifically, the funding is allocated to two entities for distinct but related purposes:Aspect Biosystems The investment will support the development and commercialization of Aspect's bioprinting technology, which is used to create therapeutic tissues. This initiative aims to advance Canadian-made biomanufacturing platforms, moving the research from the lab to commercial production.Providence Health Care (PHC) The funding will support PHC in establishing a new Cell and Gene Therapy (CGT) facility. This facility will be used to manufacture clinical-grade cell and gene therapies, supporting clinical trials, research, and future patient treatments.Overall, this investment is intended to secure domestic capacity in the life sciences sector, create high-quality jobs, and improve Canada's preparedness for future health challenges. Mark Carney on Infrastructure The Alto High-Speed Rail (HSR) project is the most ambitious transportation initiative in modern Canadian history. Formerly referred to as "High Frequency Rail" (HFR), the project evolved in 2025 into a full high-speed rail plan under Alto, a dedicated Crown corporation. For Canada, this represents a shift from outdated, shared-track travel to a modern, electrified "backbone" connecting the country's most populous region. 1. What is Alto? Alto is a wholly owned subsidiary of VIA Rail, created to act as the project authority. It operates at arm's length from the government to manage the design, construction, and eventual operation of the rail network. The Partnership: Alto is working with Cadence, a private consortium that includes major players like CDPQ Infra, AtkinsRéalis, and Air Canada, to co-design the system.The Goal: A dedicated 1,000 km track where passenger trains no longer have to pull over for freight trains.2. Technical Scope & Route The project targets speeds of up to 300 km/h, effectively "shrinking" the distance between major hubs. Primary Corridor: Toronto – Peterborough – Ottawa – Montréal – Trois-Rivières – Québec City.Phase 1: In late 2025, the government announced that the Ottawa–Montréal segment would be the first to start construction (expected in 2029) to prove the technology and generate immediate regional benefits.Southwestern Ontario: Studies are currently underway (due late 2026) to determine how to extend this service or enhance rail connections toward London and Windsor.3. What It Means for Canada The project is being framed as a "nation-building" endeavor with three primary impacts: Economic Integration By turning the Toronto-Quebec City corridor into a single, fluid economic zone, Alto aims to boost Canada's GDP by an estimated $35 billion. It allows people to live in more affordable cities (like Peterborough or Trois-Rivières) while working in major financial hubs. Environmental Goals The network will be fully electrified, significantly reducing the carbon footprint of travel in the corridor. It is designed to lure travelers away from short-haul flights and car trips on the congested Highway 401. Operational Reliability Currently, VIA Rail shares tracks with CN and CP freight trains, leading to frequent delays. Alto's dedicated tracks mean: Frequency: Trains departing every few minutes during peak hours.On-time performance: Targeted at 95% or higher.Travel Times: Dramatic reductions, such as Toronto to Ottawa in roughly 2.5 to 3 hours (down from 4.5+).4. Challenges and Criticism Despite the excitement, the project faces significant hurdles as of 2026:Cost: Estimates range from $60 billion to $90 billion, leading to political pushback regarding the use of public funds.Route Disputes: Rural communities and agricultural associations along the proposed "northern route" (through Peterborough) have raised concerns about land use and environmental disruption.Political Divide: While the current government views it as essential infrastructure, opposition leaders have criticized the high price tag, calling for more scrutiny on the project's long-term viability.Current Status (April 2026): Alto is currently conducting extensive field studies and public consultations across Ontario and Quebec to finalize the exact path of the tracks.Become a supporter of this podcast: https://www.spreaker.com/podcast/policy-and-rights--3339563/support.

For years, mammalian cells and microbial systems have dominated the biotech landscape, shaping the economics and access to life-saving biologics. Yet, in countries where capital and infrastructure are limited, those gold-standard systems bring hefty price tags and daunting complexity. The answer isn't bigger bioreactors; it's alternative biomanufacturing approaches, such as molecular farming. Imagine medicines grown like crops, ready for harvest in days, not months.Meet Waranyoo Phoolcharoen, Co-Founder and CTO of Baiya Phytopharm and Professor at Chulalongkorn University in Bangkok, a scientist who didn't settle for the status quo. As the driving force behind the company, she led the charge to cut through process bottlenecks: navigating regulatory hurdles, scaling plant-based vaccine manufacturing to 5 million doses per month, and reshaping the approach to antibody production for oncology and infectious diseases. Her work proved that plants aren't an alternative. They're a platform.Topics discussed include:How plant-based molecular farming compares to traditional microbial and mammalian cell systems (02:44)The flexibility and rapid scalability of using plants for biomanufacturing (05:06)Speeding up process development with transient expression versus transgenic plants (05:45)Regulatory perspectives and the approval process for plant-produced biologics (06:52)An overview of the ongoing oncology and infectious disease antibody pipeline (08:08)Strategic challenges: balancing product development, revenue, and market-ready innovations through subsidiary companies (09:51)Lessons learned from building a GMP facility capable of 5 million doses per month during the pandemic, with supply chain as the biggest bottleneck (12:50)Future innovations in molecular farming and the role of plant platforms in medicine production (14:47)Smart insight:Platform choice matters. If you're struggling with long development timelines or scale-up challenges, it may not always be the molecule. It may be the system you're using. Molecular farming offers a different set of trade-offs: faster development, flexible scaling, and a practical alternative worth considering before defaulting to a single platform.If you're interested in other unconventional biological platforms reshaping biomanufacturing, don't miss these episodes exploring emerging production technologies:Episodes 141 - 142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel BardorEpisodes 163 - 164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas SchaafEpisodes 229 - 230: Cyanobacteria Biomanufacturing: Achieving Carbon-Neutral Production at Lower Cost Than Fermentation with Tim CorcoranConnect with Waranyoo Phoolcharoen:Email: Waranyoo.P@baiyaphytopharm.comBaiya Phytopharm website: www.baiyaphytopharm.comNext step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show

Imagine producing life-saving antibodies or vaccines not in sprawling stainless steel facilities, but in sunlit greenhouses, inside living, breathing plants.Waranyoo Phoolcharoen, Co-Founder and CTO of Baiya Phytopharm and Professor at Chulalongkorn University in Bangkok, leads the charge in molecular farming in Thailand, pioneering a shift from traditional biomanufacturing toward using whole plants as responsive biofactories. With a unique background in both pharmaceutical sciences and plant biotechnology, she has taken her research out of the academic silo and into the world, founding a clinical-stage company determined to make vaccines and therapeutic proteins accessible where they're needed most.In this episode, we cover:Waranyoo Phoolcharoen's personal journey: from an accidental start in plant biotechnology to making a global impact with molecular farming (03:57)The pivotal moment that shifted her focus from publishing papers to translating research into real-world solutions (06:12)The initial steps and uncertainties of co-founding Baiya Phytopharm in Thailand (07:12)How 'the plant of life' philosophy drives their biopharma platform, and why whole plants (not just cell cultures) are used as biofactories (09:56)Key mindset shifts when transitioning from academia to entrepreneurship, including the importance of teamwork and commercial thinking (12:55)Strategies for making impact-driven biotech startups in resource-constrained environments, and why courage and speed matter (15:50)Insights into the biotech and pharmaceutical landscape in Southeast Asia, including opportunities and challenges for innovators (19:27)Smart insight:The most important mindset shift from scientist to entrepreneur isn't technical; it's learning to ask different questions. Not "is this interesting?" but "who will pay for this, and does it make commercial sense?" As Waranyoo puts it, when you have the right question, it leads to the right answer.Stay tuned for Part 2, where we'll explore platform capabilities and Asia's first plant-derived COVID-19 vaccine to enter clinical trials.If you're interested in other unconventional biological platforms reshaping biomanufacturing, don't miss these episodes exploring emerging production technologies:Episodes 141 - 142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel BardorEpisodes 163 - 164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas SchaafEpisodes 229 - 230: Cyanobacteria Biomanufacturing: Achieving Carbon-Neutral Production at Lower Cost Than Fermentation with Tim CorcoranConnect with Waranyoo Phoolcharoen:Email: Waranyoo.P@baiyaphytopharm.comBaiya Phytopharm website: www.baiyaphytopharm.comNext step:Need fast CMC guidance? → Get rapid CMC decision support hereOne bad CDMO decision can cost you two years and your Series A. If you're navigating tech transfer, CDMO selection, or IND prep, let's talk before it gets expensive. Two slots open this month.Support the show

Join Ankit Alok Bagaria, Co-Founder and CEO of Loopworm, for a deep dive into the future of industrial biotechnology. As a pioneer in the Indian deep-tech scene, Ankit is leveraging the natural biological efficiency of silkworms to create a massive biomanufacturing platform. In this episode, we explore why insects are the key to a protein-deficient world and how Loopworm is looking beyond the plate to apply insect-derived proteins to health, diagnostics, and high-tech manufacturing.

Sophia Xu, cofounder of Carbon Bridge, joins us to discuss how her company is revolutionizing gas fermentation with notebook-sized modular bioreactors that convert waste gases into valuable fuels and chemicals. From rejecting medical school to focus on climate biotech, to developing reactors 80% more energy efficient than traditional methods, Sophia shares how Carbon Bridge's platform enables wild-type methanotrophs to perform 500% better than genetically modified microbes. The conversation explores distributed manufacturing, the company's vision for an "app store" of microbial pathways, partnerships with Norwegian Cruise Lines, and why Sophia believes biology—not electrification—is key to decarbonizing heavy industry. We discuss deployment scenarios from dairy farms to breweries, the misconceptions about gas fermentation, and how Carbon Bridge is creating a new business model by selling bioreactors rather than end products.Grow Everything brings the bioeconomy to life. Hosts Karl Schmieder and Erum Azeez Khan share stories and interview the leaders and influencers changing the world by growing everything. Biology is the oldest technology. And it can be engineered. What are we growing?Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.messaginglab.com/groweverything⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Chapters:(00:00:00) - Sophia's Journey from Cancer Research to Climate Biotech(00:03:18) - AI in Biomanufacturing(00:06:00) - From Nanotechnology to Waste Gas Conversion(00:09:00) - Sophia's Path: Why Climate Over Medical School(00:11:00) - Biology as an Industrial Platform(00:11:48) - Visualizing Carbon Bridge: MacBook-Sized Bioreactors(00:14:00) - Navigating Unpredictability in Biological Systems(00:16:43) - Methanotrophs: The Wild-Type Microbes Behind the Tech(00:17:00) - Scaling by Stacking: From Lab to 80X Scale(00:18:00) - Sustainability Meets Economics: No Green Premium Required(00:21:00) - Performance Numbers: 80% More Efficient, 500% Better Than GMOs(00:23:00) - Distributed Manufacturing and the Server Farm Analogy(00:25:00) - Deployment Scenarios: Dairy Farms, Breweries, and Beyond(00:27:00) - Funding Insights: What ARPA-E, IndieBio, and SOSV Taught Them(00:28:53) - Business Model: Selling Bioreactors, Not End Products(00:30:00) - The App Store Vision for Microbial Pathways(00:32:00) - Carbon Conversion Over Carbon Removal(00:34:00) - Visioneering the Future: Reproducibility and the Biotech Revolution(00:36:00) - Quick Fire: Climate Myths, Hydrogen Skepticism, and More(00:39:00) - Post-Interview Reflections and Business Model SpinLinks and Resources:Links for Sophia's XuTopics Covered:CarbonBridge, climate biotech, gas fermentation, methane to methanol, modular bioreactor, distributed biomanufacturing, waste gas conversion, renewable methanol, industrial biotechnology, biomanufacturing infrastructureHave a question or comment? Message us here:Text or Call (804) 505-5553⁠⁠⁠Instagram⁠⁠⁠ / ⁠⁠⁠Twitter⁠⁠⁠ / ⁠⁠⁠LinkedIn⁠⁠⁠ / ⁠⁠⁠Youtube⁠⁠⁠ / ⁠⁠⁠Grow Everything⁠⁠⁠Music by: Nihilore Production by: Amplafy Media

What if the future of sustainable manufacturing required no sugar feedstocks, generated minimal waste, and operated carbon-neutral from day one? Ocean-derived cyanobacteria are making this possible—but the path from promising strain to profitable business is littered with synthetic biology casualties. This episode reveals the strategic decisions that separate winners from failures.In Part 2, Tim Corcoran, CEO and Co-Founder of Deep Blue Biotech, exposes the hard truths about commercializing photosynthetic manufacturing: why most synthetic biology companies died when capital dried up in 2023, which infrastructure gaps nearly derail cyanobacteria scale-up, and why building one facility beats building ten. With three decades navigating commercial biotech and operations, Tim shares the disciplined commercialization framework that transforms scientific breakthroughs into economically viable platforms.Topics covered:The strategic advantage of B2B commercialization in consumer care biotech (02:46)Overcoming infrastructure limitations for photobioreactor scale-up and partnering with specialized CMOs (04:50)Building a pilot facility and moving toward technology licensing for global reach (05:33)Location choices for production facilities—comparing natural light, skilled labor, and electricity costs in Portugal and Iceland (08:57)Impact of electricity usage for LED-supported photosynthesis on business viability (10:45)What distinguishes successful laboratory-to-market biotech companies from those that fail, especially in challenging financial environments (11:53)Practical advice for scientists considering entrepreneurship, including partnering with business-minded collaborators and exploring university innovation programs (14:08)Speculation on the broader applications and future of synthetic biology, from biofuels to biodegradable materials and CO₂-absorbing products (15:27)The importance of aligning technical innovation with commercial expertise to create enduring impact (16:38)Strategic insight:Breakthrough science needs disciplined commercialization. Align what your technology naturally excels at with market needs, start where value is highest, and leverage partnerships to scale. As Deep Blue Biotech shows, this is how innovations move from the lab to making a real-world impact.Explore the full story and hear Tim's advice for both founders and innovators.If you're interested in other unconventional biological platforms reshaping biomanufacturing, don't miss:Episode 163-164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas SchaafEpisodes 141-142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel BardorConnect with Tim Corcoran:LinkedIn: www.linkedin.com/in/tim-corcoran-5b10121/Deep Blue Biotech: www.deepbluebiotech.comNext step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show

The chemicals industry remains locked into carbon-intensive, fossil-based manufacturing. Even engineered microbes like yeast or E. coli depend on expensive sugar feedstocks while generating significant waste. What if a photosynthetic organism could eliminate those constraints entirely—while commanding premium pricing as "ocean-derived"?On the Smart Biotech Scientist Podcast, Tim Corcoran, CEO and Co-Founder of Deep Blue Biotech, reveals how a recently discovered fast-growing marine cyanobacteria strain is unlocking carbon-neutral chemical production at costs below conventional fermentation. With his background spanning economics, operations, and innovation commercialization, Tim challenges conventional assumptions about synthetic biology scale-up, market entry strategy, and what actually separates successful biotechs from valley-of-death casualties.Key topics discussed:Tim Corcoran's background in commercial roles, his pivot to biotech, and the founding story of Deep Blue Biotech (03:41)Overview of cyanobacteria biology: photosynthetic efficiency and its legacy in Earth's atmosphere (07:22)What makes the discovered ocean-based strain unique—and its advantages in robustness, growth rate, and use in personal care (08:27)Commercial challenges and scientific limitations that have made cyanobacteria difficult to industrialize—plus recent breakthroughs (9:38)Comparison with legacy hosts such as E. coli, yeast, microalgae: efficiency, feedstocks, genetic tractability, and downstream processing(11:02)The significance of direct secretion for lowering production costs and reducing CO₂ footprint (14:38)Scale-up strategies with photobioreactors: modularity, light and CO₂ management, and future tech improvements (15:17)Commercial strategy: starting with high-value personal care hyaluronic acid, regulatory considerations, and the rationale for this approach (17:17)The importance of aligning scientific innovation with market needs and early customer discovery (20:31)Long-term vision: potential for cyanobacteria in sustainable production of commodity chemicals like biofuels and the impact on global emissions (22:04)Strategic insight:Deep Blue Biotech's "premium-first commercialization" mirrors Tesla's playbook: start with high-margin applications ($2,000/kg hyaluronic acid for personal care) to generate immediate revenue and prove the platform. These early profits fund continuous strain engineering and process optimization, progressively driving down cost-of-goods while improving volumetric productivity. Only after establishing economic viability at premium pricing does the company target large-volume commodity markets—sustainable fuels, industrial chemicals—where success requires demonstration of competitive economics at industrial scale.Discover how this photosynthetic organisms could decarbonize entire chemical supply chains while improving manufacturing economics. Part 2 reveals the strategic decisions separating synthetic biology winners from failures, photobioreactor infrastructure challenges, and why licensing beats building multiple facilities.If you're interested in other unconventional biological platforms reshaping biomanufacturing, don't miss:Episode 163-164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas SchaafEpisodes 141-142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel BardorConnOne bad CDMO decision can cost you two years and your Series A. If you're navigating tech transfer, CDMO selection, or IND prep, let's talk before it gets expensive. Two slots open this month.Support the show

John Cumbers returns to the Grow Everything podcast for his fourth appearance to discuss the cutting edge of synthetic biology and the upcoming SynBioBeta 2026 conference. From a man who's been bitten by snakes over 200 times to create universal anti-venom, to the race between the US and China in bio-manufacturing, John reveals why the bioeconomy is reaching an inflection point. We explore how AI is transforming organism design, the $50 million deals being struck for AI models in pharma, and why Chinese bio-manufacturing firms are achieving profitability while Western companies struggle. John also shares his vision for cellular reprogramming and longevity, discusses the controversial rollback of US environmental policy, and explains why the "ChatGPT moment" for biology is closer than we think. Plus, learn about stem cell tissue banks that could revolutionize replacement therapy and why SynBioBeta 2030 will actually happen on the moon.Grow Everything brings the bioeconomy to life. Hosts Karl Schmieder and Erum Azeez Khan share stories and interview the leaders and influencers changing the world by growing everything. Biology is the oldest technology. And it can be engineered. What are we growing?Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.messaginglab.com/groweverything⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Chapters:(00:00:00) - Welcome Back: John Cumbers' Fourth Appearance on Grow Everything(00:01:00) - Death Becomes Her: Longevity on Broadway(00:03:00) - Listening Bars and Ambient Music Experience(00:04:00) - The Peptide Revolution: From Gray Market to Mainstream(00:07:00) - Trump Administration Revokes Clean Air Act: Impact on Biotech(00:12:00) - Biomanufacturing as Economic Development and Climate Solution(00:13:00) - AI, Space, and Solar Energy: Elon Musk at World Economic Forum(00:16:00) - Data Centers in Space: The Future of Energy(00:18:00) - Introducing John Cumbers and SynBioBeta 2026(00:19:00) - The Man Bitten by 200+ Snakes: Universal Anti-Venom Story(00:22:00) - The Schmidt Pain Index and Extreme Science(00:23:00) - History and Evolution of SynBioBeta Over 14 Years(00:25:00) - Bio 500: Big Companies Transforming with Biotech(00:27:00) - Plant-Based Sales Slowdown and Consumer Bio Trends(00:30:00) - Discovery vs. Commercialization: Why 80% of Startups Fail on Execution(00:34:00) - Default Alive Companies: Bootstrapping the Bioeconomy00:36:00) - AI Meets Biology: When's the ChatGPT Moment?(00:39:00) - Sidewinder DNA Assembly: Revolutionary Build Technology(00:42:00) - Design-Build-Test-Learn: Closing the Loop with Self-Driving Labs(00:43:00) - China's Biomanufacturing Dominance: What the West Can Learn(00:49:00) - Free Market Capitalism vs. Centralized Planning(00:52:00) - Should SynBioBeta Take Political Stands?(00:55:00) - Longevity Revolution: Cellular Programming and Stem Cell Banks(00:59:00) - Death Becomes Her and the Market for Living Forever(01:01:00) - AI and Bio: The Singularity is Here(01:03:00) - Human Genome Engineering and the Meta Simulation(01:05:00) - Quick Fire Round: Lantern Bioworks, Moon Conference, and Awards(01:07:00) - Closing: SynBioBeta Discount Code and Final ThoughtsLinks and Resources:Synbiobeta website. Join us! Use code: "Grow Everything" for a discountOneSkinReplacement theory of aging - Jean HebertTopics Covered:synbio, synthetic biology, bioengineering, conferences, networks, biotech, biology, bioliteracy, Bio500, AI and BioHave a question or comment? Message us here:Text or Call (804) 505-5553⁠⁠Instagram⁠⁠ / ⁠⁠Twitter⁠⁠ / ⁠⁠LinkedIn⁠⁠ / ⁠⁠Youtube⁠⁠ / ⁠⁠Grow Everything⁠⁠Music by: Nihilore Production by: Amplafy Media

Eva is an Associate Professor at the University of New England, where her research focuses on proteins and utilizes biochemistry, biomaterials, and biophysics. She is also deeply interested in antidisciplinary, collaborative research. Eva was a 5 Minute Genius™ speakers at the 2024 Maine Science Festival; you can see her talk on our YouTube channel. This conversation was recorded in December 2025. ~~~~~The Maine Science Podcast is a production of the Maine Discovery Museum. It is recorded at Discovery Studios, at the Maine Discovery Museum, in Bangor, ME. The Maine Science Podcast is hosted and executive produced by Kate Dickerson; edited and produced by Scott Loiselle. The Discover Maine theme was composed and performed by Nick Parker. To support our work: https://www.mainediscoverymuseum.org/donate. Find us online:Maine Discovery MuseumMaine Discovery Museum on social media: Facebook Instagram LinkedIn Bluesky YouTubeMaine Science Podcast on social media: Facebook Instagram YouTubeMaine Science Festival on social media: Facebook Instagram LinkedIn YouTube© 2026 Maine Discovery Museum

Karl and Erum break down how biology is transforming the production of everything from cosmetics to construction materials. They explore why the petrochemical era is giving way to biological manufacturing, examining both the spectacular failures of early biofuels and the emerging success stories of companies like K18 and Mango Materials. Karl and Erum explain the fundamentals of fermentation, precision fermentation, and cell-free manufacturing, while introducing concepts like distributed biomanufacturing and "dirty biology." Drawing on insights from previous guests including Doug Friedman, Michelle Stansfield, Veronica Breckenridge, and Phil Morle, they reveal why 95% of executives are now pursuing bio-solutions and how three converging forces—falling technology costs, rising consumer expectations, and new infrastructure—are making this the moment for biomanufacturing to finally deliver on its promise.Grow Everything brings the bioeconomy to life. Hosts Karl Schmieder and Erum Azeez Khan share stories and interview the leaders and influencers changing the world by growing everything. Biology is the oldest technology. And it can be engineered. What are we growing?Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.messaginglab.com/groweverything⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Chapters:(00:00:00) - Why AI might just become our CEO (plus haircuts, Pilates, and gene therapy for hearing loss)(00:02:05) - Eli Lilly's $1B gene therapy deal for hearing loss(00:05:00) - Long Now podcast recommendation and NASA astrobiologist Lynn Rothschild(00:07:00) - Discussion of Apple TV's Scion and Drops of God(00:11:00) - What is biomanufacturing and why does it matter?(00:13:00) - The history of petrochemicals as "green technology"(00:16:00) - The opportunity: removing gigatons of carbon and unlocking trillion-dollar markets(00:19:00) - Types of biomanufacturing: fermentation, precision fermentation, and continuous fermentation(00:22:00) - Cell-free manufacturing and plant cell bioreactors(00:26:00) - Growing products with mycelium and dirty biology approaches(00:29:00) - Why biomanufacturing has been hard: the valley of death(00:30:00) - The biofuels bust and lessons from 60 failed companies(00:34:00) - Infrastructure challenges and the capacity gap(00:36:00) - New solutions: performance over sustainability and the K18 example(00:40:00) - Orchestration beats invention: connecting the entire value chain(00:43:00) - Distributed biomanufacturing and making products from waste(00:48:00) - The bio-better reality: what consumers and CPG companies need(00:51:00) - Three forces converging to make biomanufacturing work now(00:53:00) - Quickfire questions: luxury vs. commodities, funding, and AI's roleLinks and Resources:Links and Resources DOCTopics Covered: biomanufacturing 101, industrial biotechnology, precision fermentation, continuous fermentation, cell-free biomanufacturing, distributed biomanufacturing, dirty biology, bio-based materials, performance vs sustainability, CPG reformulationHave a question or comment? Message us here:Text or Call (804) 505-5553⁠Instagram⁠  / ⁠Twitter⁠ / ⁠LinkedIn⁠ / ⁠Youtube⁠ / ⁠Grow Everything⁠Music by: Nihilore Production by:  Amplafy Media

Most biotech breakthroughs don't fail in the lab.They fail when science meets manufacturing reality.And by the time this bottleneck appears, tens of millions are already sunk.This episode examines the most under-discussed failure point in modern biotech: the gap between scientific discovery and scalable, usable healthcare solutions.While science has never been stronger—and big pharma excels at market access—companies that can translate breakthrough biology into industrialized medicines remain rare. Manufacturing, regulation, clinical design, usability for patients and physicians, and global scalability still form a narrow bottleneck where most value is lost.In this conversation, Björn Cochlovius, CEO of Eleva, explains why so many promising biologics fail late—and how Eleva deliberately built a platform designed not to replace existing systems, but to rescue projects that would otherwise be abandoned.Drawing on decades across immunology, biotech leadership, and translational medicine, Björn offers a grounded, operator-level view on what it actually takes to move from elegant science to real-world impact.As he puts it:(00:28:59) “In biotech, courageous decisions often look wrong—until years later.”This discussion goes beyond manufacturing alone. It explores why turning scientific concepts into ready-to-deploy healthcare solutions—complete with clinical data, regulatory pathways, scalable production, and high usability—remains one of the hardest industrial challenges of our time.What You'll Learn in This Episode1️⃣ Why biologics often fail late—after science already worked2️⃣ Why manufacturing is only one part of a deeper industrial bottleneck3️⃣ How Eleva approaches risk when others walk away4️⃣ Why courage, not optimization, drives breakthrough biotech decisions5️⃣ How AI supports discovery—without replacing human judgment6️⃣ What Europe gets right—and still gets wrong—about scaling biotech

Joshua Lachter, co-founder of Synonym, joins us for an in-depth conversation about the future of biomanufacturing and what he calls "the great reformulation." We explore how biology is poised to replace petrochemicals across industries, the infrastructure challenges holding back commercial scale production, and why standardization is critical for mass adoption. Joshua shares insights from Synonym's work building commercial biomanufacturing facilities, including their groundbreaking project in Decatur, Illinois. From GLP-1s to microplastics, we discuss how bio-based products can deliver superior performance while addressing health and environmental concerns. This episode is essential listening for anyone interested in the commercialization of industrial biotech, the economics of biomanufacturing, and the path toward a reformulated supply chain built on biology.(00:00:00) - Snowstorm updates from NYC(00:03:00) - Tech Meets Pharma: The Data Revolution(00:09:00) - Mr. Beast, Upside Foods, and Colossal Biosciences(00:14:00) - Joshua's Background and Why He Founded Synonym(00:18:00) - Financialization and Standardization of Biomanufacturing(00:25:00) - Early Assumptions That Turned Out Wrong(00:38:00) - The Great Reformulation: Biology vs. Petrochemicals(00:48:00) - GLP-1s and Nature-Inspired Innovation(00:54:00) - Better with Bio: Synonym's Partnership with Brentag(00:59:00) - Quickfire Questions(01:03:00) - Wrap-Up & Final ThoughtsEpisode Links:SynonymBetterWith.BioThe Great Reformulation Primient and Synonym Forge Strategic Partnership to Propel U.S. Bioproduct InnovationNYC Mayor Zohran Mamdani Snowstorm Prep VideoMr. Beast video: $1 vs $1,000,000,000 Futuristic Tech!Edward Shenderovich epAmy Trejo and JC Garcia Garcia epSuveen K18 ep Grow Everything brings the bioeconomy to life. Hosts Karl Schmieder and Erum Azeez Khan share stories and interview the leaders and influencers changing the world by growing everything. Biology is the oldest technology. And it can be engineered. What are we growing?Learn more at www.messaginglab.com/groweverythingTopics Covered: biotech, industry, biomanufacturing, bioprocessing, industrial biotech, Great Reformulation, consumer packaged goods, CPG, biotech R&D, chemical engineering, bioengineering, AI in biomanufacturingHave a question or comment? Message us here:Text or Call (804) 505-5553Instagram  / Twitter / LinkedIn / Youtube / Grow Everything

- Ismael Nieves, General Manager, Primient iPROOF  - Vijay Singh, IBRL University of Illinois  ★ Support this podcast ★

Guest: Dr. Pinar Mesci is the Global Head of Biomanufacturing and Biotechnology at Axiom Space, where she manages a portfolio focused on biomedical research programs including stem cells, tissue engineering, disease modeling, cancer research, and DNA-inspired nanomaterials. She talks about her early career developing brain organoid models, transitioning to the space industry, and how microgravity affects biological systems. She also discusses the future of low Earth orbit research and how new technologies can be transferred back to Earth. (40:55) Featured Products and Resources: Submit your abstract for ISSCR 2026 by February 25th! Take your human pluripotent stem cell cultures further with mTeSR™ Plus from STEMCELL Technologies. The Stem Cell Science Round Up iPSC-Derived Ovarian Support Cells – Fertilo is an ovarian support cell product that improves the in vitro maturation rate of human oocytes. (1:25) Culturing HSPCs Ex Vivo – A nanoengineered 3D system improves HSPC multi-lineage differentiation and engraftment capacity. (13:30) Spinal Core Repair Scaffolds – A nanoengineered extrusion-aligned tract promotes axonal reconnection, synapse formation, and locomotor recovery after spinal cord injury. (22:50) Vascularizing Retinal Organoids – Transient vascular support enhances survival of retinal ganglion cells in organoids. (32:14) Image courtesy of Dr. Pinar Mesci Subscribe to our newsletter! Never miss updates about new episodes. Subscribe

For generations, silkworm pupae were discarded as waste from silk production. Now, KAICO is proving these organisms can function as highly efficient protein factories—producing complex vaccine antigens at yields and costs that challenge conventional bioreactor-based manufacturing. With a PCV2 oral vaccine already registered in Vietnam and a human norovirus vaccine preparing for Phase I clinical trials, the silkworm platform is moving from proof-of-concept to commercial reality.In Part 2, Masafumi Osawa, Business Development Lead at KAICO, walks us through the company's product pipeline, the regulatory landscape for this unprecedented platform, and why silkworm-based manufacturing could reshape global vaccine accessibility. From farm-scale validation to regulatory dialogue with Japan's PMDA, this episode bridges platform science with product development.Stops along our Silk Road to biomanufacturingKAICO's approach to expressing complex proteins, including oral and injectable vaccines for animals and clinical-stage human health products (00:40)Immune-enhancing feed additive for pigs against PCV2 (registered in Vietnam), companion animal products, and human norovirus vaccine entering Phase 1 trials (02:50)Advantages of silkworm-produced antigens for both injectable and oral vaccines, and comparison to plant-based systems (04:57)How silkworm production enables rapid scale-out and high-yield protein expression for global accessibility (05:34)Speed of vaccine development with the silkworm platform—example with SARS-CoV-2 recombinant protein produced in three months (08:08)Key regulatory differences between animal and human vaccine development, including country-specific classification and global harmonization efforts (09:14)Sustainability and distributed manufacturing potential of silkworm-based systems (11:10)Milestones toward the first human biologic produced in silkworms, with phase 1 trials starting soon (12:27)Protein yield per silkworm pupae—scalability advantages compared to conventional bioreactor approaches (14:04)Masafumi Osawa's thoughts on the future of silkworm-based biologics: from democratized therapies to personalized medicines (15:15)Want to know if silkworms can solve your tough protein expression problems? Tune in now to learn how KAICO's biotech is set to redefine what's possible for vaccine development, and how their distributed, cost-effective approach could open doors across sectors.Connect with Masafumi Osawa,:LinkedIn: www.linkedin.com/in/masa-osawaKAICO Ltd.: www.kaicoltd.jp/enNext step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show

For over 4,000 years, silkworms have connected civilizations through ancient trade routes. Now, KAICO Ltd., a Japanese biotech spin-off from Kyushu University, is transforming these creatures into living bioreactors capable of producing complex recombinant proteins and vaccine antigens—without the bioreactors, expensive media, or massive water consumption of conventional platforms.Masafumi Osawa, Business Development Lead at KAICO, brings an unconventional path to biotech. Trained in cultural anthropology with fieldwork experience in Indonesia, he witnessed firsthand the healthcare disparities that drive his current mission. After years in pharmaceutical business development at Towa Pharmaceutical, he joined KAICO to help scale a technology he believes could reshape global vaccine accessibility. His cross-cultural expertise now proves invaluable as KAICO expands internationally, with active partnerships in Vietnam and Thailand and growing interest from other regions.Episode highlights:Masafumi's transition from anthropology to biotech, and how cross-cultural expertise benefits global health collaborations. (04:15)The founding story of KAICO, spun out from Kyushu University and focused on recombinant proteins and vaccine antigen production (08:45)Step-by-step overview of the silkworm baculovirus expression system, including pupae handling and bioprocessing basics. (10:28)Practical differences between silkworms, E. coli, mammalian, and insect cell culture platforms—exploring advantages and drawbacks. (13:10)Strategies KAICO uses to control silkworm variability, including SPF grade sourcing, diet, environment, and documentation for pharmaceutical acceptance. (15:08)Production scalability: a single pupa can match 100–1000 ml of insect cell culture, with major implications for cost and environmental footprint. (16:42)Downstream harvesting and purification—how KAICO extracts and processes proteins from silkworm pupae, keeping methods largely familiar to traditional systems. (19:31)Regulatory and GMP challenges of using live organisms, and KAICO's approach to satisfying authorities and ensuring product consistency. (21:43)Whether you're curious about alternative biomanufacturing methods or want a transparent look at silkworm-based protein expression from research to the clinic, this episode delivers practical insights and thoughtful discussion.Connect with Masafumi Osawa:LinkedIn: www.linkedin.com/in/masa-osawaKAICO Ltd.: www.kaicoltd.jp/enNext step:Need fast CMC guidance? → Get rapid CMC decision support hereOne bad CDMO decision can cost you two years and your Series A. If you're navigating tech transfer, CDMO selection, or IND prep, let's talk before it gets expensive. Two slots open this month.Support the show

Ismael Nieves, General Manager, Primient iPROOF  Vijay Singh, IBRL University of Illinois From the Land Grant University in Urbana-Champaign, Illinois this is a special edition of the Closing Market Report. Presentations from the 2025 Farm Assets Conference; BioManufacturing and the Future of Ag.  During the conference, Vijay Singh and Ismael Nieves discussed the future of precision fermentation in Illinois, focusing on the role of iFAB or the Illinois Fermentation and Agriculture Biomanufacturing Tech Hub. Vijay Singh from the University of Illinois started the conversation. ★ Support this podcast ★

Welcome to another enlightening episode of "The Brand Called You," where host Ashutosh Garg sits down with Justin Byers, Founder and CEO of Axio BioPharma. Axio is a pioneering AI biomanufacturing company, transforming how monoclonal antibodies and biologics are developed and produced by integrating artificial intelligence and machine learning into drug design and manufacturing processes.In this episode, Justin Byers shares his unique journey from scientist to entrepreneur, the inefficiencies he noticed in traditional biomanufacturing, and how Axio BioPharma accelerates drug development timelines, reduces risk, and ensures regulatory compliance—all while respecting data privacy. Discover how cross-functional teams, AI-driven predictive modeling, and federated data systems are creating real impact in healthcare, making treatments more accessible and paving the way for innovation in rare disease therapies.Whether you're interested in biotech innovation, AI applications in healthcare, or the future of drug manufacturing and delivery, this conversation is filled with valuable insights and practical lessons.

Biomanufacturing has always dealt with the challenge of turning vast, complex datasets and intricate production steps into life-changing therapies. But when batch records multiply and process deviations loom, how do biotech teams make sense of it all? In this episode, we move beyond theory to the nuts and bolts of how AI - when thoughtfully deployed - can turn bioprocessing chaos into actionable intelligence, paving the way for the factory of the future.Our guest, Ilya Burkov, Global Head of Healthcare and Life Sciences Growth at Nebius AI, doesn't just talk about data wrangling and algorithms—he's spent years building tools and strategies to help scientists organize, contextualize, and leverage real-world datasets. Having worked across tech innovation and pharmaceuticals, Ilya Burkov bridges cutting-edge computation with the practical realities of CMC development and manufacturing, making him a trusted voice on how bioprocessing is rapidly changing.Highlights from the episode:Advice for biotech scientists on learning from innovations in other industries (00:02:21)Tackling the complexities of organizing huge and often unstructured datasets in bioprocessing (03:08)Techniques and tools to structure, label, and prepare data for AI—including Nebius's in-house tool, Tracto AI (06:24)Strategies for startups and small teams—how to begin implementing AI and what areas of bioprocessing to focus on first (10:12)The vision for the “factory of the future”: AI-driven, interconnected, and self-learning manufacturing environments (08:11)Navigating the decision between on-premise and cloud computing for scalable, cost-effective AI workloads (12:32)The importance of partnership between scientists and AI, emphasizing collaboration and data-driven decisions (00:15:47)Wondering how to kick off your own AI-enabled bioprocessing project, or what to insource versus outsource as you scale? This episode gives you a grounded starting point—minus the buzzwords and empty promises.Connect with Ilya Burkov:LinkedIn: www.linkedin.com/in/ilyaburkovContact email: ilya.burkov@nebius.comNebius: www.nebius.comIf this topic grabbed you, you'll love these related episodes focusing on advanced modeling, continuous manufacturing, and Digital TwinsEpisodes 213 - 214: From Developability to Formulation: How In Silico Methods Predict Stability Issues Before the Lab with Giuseppe LicariEpisodes 85 - 86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo MorbidelliEpisodes 05 - 06: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael SokolovEpisode 153 - 154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago MatosEpisodes 173 - 174: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist GernaeyNext step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show

Across biotech labs, researchers swim in oceans of process data: sensor streams, run records, engineering logs, and still, crucial decisions get stuck in spreadsheets or scribbled into fading notebooks. The challenge isn't having enough information, it's knowing which actions actually move the needle in cell culture productivity, process stability, and faster timelines.This episode, David Brühlmann brings on Ilya Burkov, Global Head of Healthcare and Life Sciences Growth at Nebius AI. With a career spanning NHS medicine, regenerative research, and cloud infrastructure, Ilya Burkov has lived the leap from microscope to server room. He's seen firsthand how digital twins, autonomous experimentation, and cloud-first strategies are shifting the way biologics are developed and scaled.Topics discussed:Shifting from experimental-based to computational bioprocess development, and the evolving role of human expertise vs. AI (02:48)Ilya Burkov's journey from medicine and orthopedics to AI and cloud infrastructure (04:15)Solving data silos and making real-time decisions with digital twins and automated analytics (06:36)The impact of AI-driven lab automation and robotics on drug discovery timelines (08:51)Using AI to accelerate cell line selection, cloning, and protein sequence optimization (10:12)Why wet lab experimentation is still essential, and how predictive modelling can reduce failure rates (11:15)Reducing costs and accelerating development by leveraging AI in process screening and optimization (12:32)Strategies for smaller companies to effectively store and manage bioprocess data, including practical advice on cloud adoption and security (14:30)Application of AI and digital twins in scale-up processes, and connecting diverse data types like CFD simulations and process data (17:18)The ongoing need for human expertise in interpreting and qualifying data, even as machine learning advances (19:09)Wondering how to stop your own data from gathering dust? This episode unpacks practical strategies for storing and leveraging your experimental records - whether you're in a major pharma or a small startup with limited tech resources.Connect with Ilya Burkov:LinkedIn: www.linkedin.com/in/ilyaburkovContact email: ilya.burkov@nebius.comNebius: www.nebius.comIf this topic grabbed you, you'll love these related episodes focusing on advanced modeling, continuous manufacturing, and Digital TwinsEpisodes 213 - 214: From Developability to Formulation: How In Silico Methods Predict Stability Issues Before the Lab with Giuseppe LicariEpisodes 85 - 86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo MorbidelliEpisodes 05 - 06: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael SokolovEpisode 153 - 154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago MatosEpisodes 173 - 174: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist GernaeyNext step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show

Dr. Margaret Bryans, Biology Professor and coordinator of the Biotechnology Program at MCCC, talks about her recent BioBuzz Workforce Champion of the Year Award, and gives an overview of her work to educate and train biotechnology and biomanufacturing of students for the Philadelphia region's science workforce.Recorded by Quinn Szente and Ian Meranus, edited by Quinn Szente from the College's Sound Recording and Music Technology Program

Carbon neutrality goals are everywhere in biopharma. But how do you actually measure and reduce your true environmental impact when data gaps and baseline differences make comparisons so tough?In this episode, David Brühlmann talks with Niklas Jungnelius, Cytiva's expert in process modeling and sustainability, who's spent years uncovering what really drives emissions and how small process tweaks can deliver big results.Niklas goes beyond the numbers, challenging assumptions and showing how sustainability becomes a strategic, data-driven advantage. From real-world cases at Cytiva, he explains why recycling plastics may not move the needle and why the real gains often lie in hotspots like cleanroom energy use and raw material choices.Here's why this episode will make you rethink your next facility upgrade:Understanding life cycle assessment and the key damage categories in environmental sustainability, including carbon emissions, water usage, and resource depletion. (00:00)The challenge of defining carbon emissions baselines and why it's harder, and often more expensive, to achieve deep reductions if your operations already use clean energy sources. (03:06)Why the focus on recycling single-use plastics may not be the most effective route for lowering emissions, and what truly drives carbon footprint in bioprocessing. (05:54)The impact of production scale, consumables, and obscure chemicals on the overall environmental impact and how these surprises can shift sustainability strategies. (06:20)Practical advice for scientists and engineers: How to start monitoring and modeling environmental impact in process development and manufacturing. (08:00)The importance of involving manufacturing perspectives early in process development, and choosing the right level of detail and ambition for process modeling. (08:18)There's no one-size-fits-all in manufacturing technology—whether fed-batch, continuous, or hybrid and decisions must fit each organization's needs, resources, and ambitions. (10:13)Industry trends that could transform the field, from intensified fed-batch production to future technologies like cell-free expression systems. (11:22)Where to connect with Niklas for further questions or collaboration. (14:03]Whether you're an early-stage startup, a strategic advisor, or on the front lines of bioprocess development, this episode invites you to rethink your sustainability strategy and modeling approach. Check out the below links to connect with Niklas Jungnelius and additional resources.Connect with Niklas Jungnelius:LinkedIn: www.linkedin.com/in/niklas-jungneliusCytiva website: www.cytivalifesciences.com/en/usNext step:Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Your Manufacturing Decisions Are Costing You More Than You ThinkEvery bioreactor decision. Every scale-up choice. Every facility investment. They're all silently writing checks your process might not be able to cash.The difference between a profitable biologics program and one that bleeds capital? Process economic modeling, the analytical framework that reveals exactly where your money goes and why.In this episode of the Smart Biotech Scientist Podcast, David Brühlmann talks with Niklas Jungnelius, Process Modeling Leader at Cytiva, who has spent 25+ years decoding the economics of biologics manufacturing for biotech companies navigating billion-dollar decisions.Niklas reveals the hidden cost drivers most teams miss, the surprising economics behind fed-batch vs. continuous processing, and why your facility choice at intermediate scale could make or break your business case.Episode Highlights:What process economic modeling is and how it differs from mechanistic modeling (06:40)Main cost drivers in biologics and biosimilars manufacturing, and their direct and indirect impacts on patient pricing (09:21)The role of manufacturing scale and productivity in driving down costs, and how facility type (stainless steel vs single-use) affects labor, flexibility, and investment (11:51)Trade-offs between single-use and stainless steel facilities at intermediate production scales (15:07)Key differences in cost and efficiency between fed-batch and fully continuous manufacturing, including productivity limitations and capital/expenditure implications (16:20)The impact of resin lifetime and under-utilization on clinical manufacturing costs (19:51)Hidden or less quantifiable costs such as facility flexibility, excess capacity, safety margins, and the importance of realistic assumptions in economic modeling (20:20)This is a grounded discussion with practical takeaways for biotech scientists seeking clarity in the complex terrain of process economics. Part two of this conversation will focus on sustainability modeling and the latest technologies reshaping bioprocessing economics.Ready to see how process modeling could transform your approach and protect your bottom line? Listen to the episode and rethink your next investment.Connect with Niklas Jungnelius:LinkedIn: www.linkedin.com/in/niklas-jungneliusCytiva website: www.cytivalifesciences.com/en/usNext step:Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

This episode explores the journey from scientific breakthrough to scalable industrial implementation. Phil Morle — partner at Main Sequence and co‑founder of Pollenizer — explains how strategic off‑takes generate market pull, the reasons nylon recycling advanced faster than PET, and the orchestration techniques required to progress from First-Of-A-Kind (FOAK) to Next-Of-A-Kind (NOAK) facilities. The conversation covers practical aspects of costs, partnership development, policy incentives, and industrial realities, including Phil's pragmatic test: "if it doesn't need a forklift, it's not relevant."Chapters:- 00:00:00 – Intro and producer mindset- 00:06:53 – Orchestration and Samsara origin story- 00:07:53 – Market pull with Woolworths and ANU enzymes- 00:11:12 – Why nylon before PET- 00:12:12 – Offtake vs. equity checks- 00:31:40 – Industrial reality: the forklift test- 00:33:56 – Samsara's infinite-recycling facility- 00:34:33 – Biomanufacturing as infrastructure- 00:40:25 – FOAK to NOAK playbooks- 00:55:00 – Cauldron's HyperFermentation infrastructureEpisode Links:- Main Sequence Ventures - https://www.mseq.vc/- Lululemon & Samsara deal - https://corporate.lululemon.com/media/our-stories/2025/lululemon-and-samsara-eco-announce-10-year-plan-to-advance-recycled-material-portfolio)- Future of Fungi Awards - https://www.futureisfungi.org/- **Michele Stansfield Episode** - https://creators.spotify.com/pod/profile/messaginglab/episodes/85--Always-Be-Brewing-Continuous-Fermentation-with-Cauldrons-Michele-Stansfield-e2lu3kdTopics Covered:venture capital, ecosystem orchestration, biotech, australian businessHave a question or comment? Message us here:Text or Call (804) 505-5553Instagram/Twitter/LinkedIn/Youtube/Grow Everything

As the biopharmaceutical industry expands, companies face a constant challenge: How do you find and train the talent needed to sustain growth? And how is technology reshaping the way we prepare the workforce?In this episode of Life Science Solutions, host Chris Adkins sits down with Dr. Gary Gilleskie, Executive Director of the Biomanufacturing Training and Education Center (BTEC) at NC State University. Together, they explore the evolution of biologics manufacturing in NC, BTEC's hybrid industry-academia training model, and the center's unique impact on workforce development in biopharma and beyondGary shares insights from decades of experience in both industry and education—from the early days of stainless-steel facilities to the rise of single-use technology, to today's booming demand for GMP-trained professionals. Topics include:How BTEC bridges academia and industry to prepare talent for biopharma careersWhy North Carolina has become a hub for biomanufacturing growthThe rise of single-use technologies and what they mean for training and efficiencyThe importance of hands-on GMP experience for students and professionals alikeThis episode highlights the strategies, infrastructure, and people driving innovation in biopharma—and why workforce development is the key to keeping pace with the industry's future.#Biomanufacturing #Biopharma #GMP

Join guest host Dr. Liz Specht for a conversation with Matt Spence, the managing director and global head of venture capital banking at Barclays. In this episode Dr. Spence discusses the role food security plays in national security and how the government can incentivize and support biotechnology research and development. The episode explores how synthetic biology can be leveraged into additional defense uses and dispels common misconceptions about synthetic biology and national security. To receive updates about the conference please join our mailing list here: https://www.emergingtechnologiesinstitute.org/sign-up http://emergingtechnologiesinstitute.org https://www.facebook.com/EmergingTechETI https://www.linkedin.com/company/ndia-eti-emerging-technologies-institute https://www.twitter.com/EmergingTechETI

Join guest host Dr. Liz Specht for a conversation with Matt Spence, the managing director and global head of venture capital banking at Barclays. In this episode Dr. Spence discusses the role food security plays in national security and how the government can incentivize and support biotechnology research and development. The episode explores how synthetic biology can be leveraged into additional defense uses and dispels common misconceptions about synthetic biology and national security.To receive updates about the conference please join our mailing list here: https://www.emergingtechnologiesinstitute.org/sign-uphttp://emergingtechnologiesinstitute.orghttps://www.facebook.com/EmergingTechETIhttps://www.linkedin.com/company/ndia-eti-emerging-technologies-institutehttps://www.twitter.com/EmergingTechETI

Cemvita is taking microbes and turning them into an entirely new playbook for energy and manufacturing. Chuck sat down with CEO Moji Karimi and BioWell's Paul Palmer to talk about how biology, AI, and genomics are teaming up to replace petrochemicals with bio-based alternatives. We're talking everything from sustainable aviation fuel to biofertilizers to underground biorefineries that sound like science fiction but are already in motion. Along the way, they unpack how biomanufacturing could clean up supply chains, cut waste, and unlock new energy sources, all while building a circular bioeconomy that makes sustainability actually scalable. If you've ever wondered what the future looks like when bugs beat barrels, this one's for you.Click here to watch a video of this episode.Join the conversation shaping the future of energy.Collide is the community where oil & gas professionals connect, share insights, and solve real-world problems together. No noise. No fluff. Just the discussions that move our industry forward.Apply today at collide.ioClick here to view the episode transcript. 00:00 - Intro00:32 - What is Zymergen02:37 - Real World Examples of Biomanufacturing05:52 - AI in Biomanufacturing Acceleration08:44 - Economics of Biomanufacturing14:04 - Company Overview and Operations18:19 - Microbiology Benefits in Oil and Gas23:47 - Contacting Doug26:10 - Current Biomanufacturing Market Size28:53 - Biodegradable Product Innovations30:30 - Nature-Inspired Technologies33:14 - Environmental Impact of Biomanufacturing38:00 - Future Trends in Biomanufacturing39:31 - What's Next for You40:50 - Bipartisan Support for Biomanufacturing43:15 - Contact Informationhttps://twitter.com/collide_iohttps://www.tiktok.com/@collide.iohttps://www.facebook.com/collide.iohttps://www.instagram.com/collide.iohttps://www.youtube.com/@collide_iohttps://bsky.app/profile/digitalwildcatters.bsky.socialhttps://www.linkedin.com/company/collide-digital-wildcatters

As pharmaceutical companies grow, they face critical choices: Where should you manufacture your product? How do you choose the right CDMO? What risks come with global supply chains?In this episode of Life Science Solutions, host Chris Adkins sits down with Roger Lias, PhD a 35-year veteran of the biologics manufacturing industry, to dig into the realities of onshoring in pharma and the evolving CDMO landscape.Roger walks through geopolitics and the BIOSECURE Act to the practical hurdles of talent shortages and infrastructure buildouts. Roger outlines what sponsor companies need to consider when choosing a domestic or international partner, from experience working in APAC. Topics include:Why “onshoring” may be more political theater than operational shiftThe labor and infrastructure gap in U.S. biologics manufacturingHow CDMO specialization is reshaping the global pharma supply chainFrom navigating regulatory risks to building smart tech transfer plans, this episode gives growing pharma teams the tools to make better decisions.

This episode's Community Champion Sponsor is Ossur. To learn more about their ‘Responsible for Tomorrow' Sustainability Campaign, and how you can get involved: CLICK HEREEpisode Overview: Life-saving drugs exist for many diseases, yet millions still lack access due to manufacturing inefficiencies and high costs. Our next guest, Reza Farahani, is revolutionizing this challenge as founder and CEO of Katalyze AI. As a third-time founder with two successful exits and strategic consulting experience at BCG, Reza brings a unique perspective to biomanufacturing optimization. His company is pioneering agentic AI solutions that act as specialized co-pilots, combining the expertise of data engineers, scientists, and process engineers into powerful automation tools. Driven by a mission to make essential medicines accessible and affordable for everyone, Reza shares how Katalyze AI is helping pharmaceutical companies increase efficiency, reduce costs, and minimize waste. Join us to discover how AI-powered biomanufacturing is transforming drug production and creating a future where life-saving treatments are within reach for all communities. Let's go!Episode Highlights:Bias Towards Action: Reza's #1 advice for entrepreneurs is taking action over endless planning - he even encourages new team members to make mistakes in their first few monthsMillion Dose Impact: Katalyze AI helped a pharmaceutical company ship one million extra vaccine doses without any capital investment, just by optimizing standard operating proceduresData Goldmine Unlocked: The company created specialized digitization tools to extract valuable insights from unstructured PDFs and lab notes that were previously inaccessibleFuture of Bio-Manufacturing: Reza envisions making everyday products like milk through bio-manufacturing at 10X lower costs with 90% less energy and 60% less waterAgentic AI Solutions: Katalyze AI acts as a specialized co-pilot combining data engineering, science, and process engineering expertise to help one person solve complex manufacturing problemsRetryClaude can make mistakes. Please double-check responses.About our Guest: Reza is a third-time founder with two successful exits, reflecting his strong track record in launching and scaling technology ventures. Before founding Katalyze AI, he gained strategic consulting experience at BCG, where he focused on driving data-driven solutions for diverse industries. He holds a Master's degree in System Design Engineering from the University of Waterloo. His leadership establishes the company as a trusted partner in biomanufacturing.Links Supporting This Episode: Katalyze AI Website: CLICK HEREReza Farahani LinkedIn page: CLICK HEREKatalyze AI LinkedIn: CLICK HEREMike Biselli LinkedIn page: CLICK HEREMike Biselli Twitter page: CLICK HEREVisit our website: CLICK HERESubscribe to newsletter: CLICK...

Perseid Meteor Shower Approaches: Get ready for the spectacular Perseid meteor shower, expected to peak around August 12th to 13th! This celestial event promises to deliver a dazzling display of meteors, with Australia being one of the best places to witness it. With up to 100 meteors per hour, this year's shower is sure to be a treat for stargazers. We share tips on how to maximize your viewing experience, from finding dark skies to letting your eyes adjust to the night.- Exploring a Cosmic Void: Dive into the latest research that suggests our Milky Way may be located within a giant cosmic void. This theory could help resolve the long-standing Hubble tension regarding the universe's expansion rate. Learn how baryon acoustic oscillations and new measurements support this intriguing hypothesis, challenging our understanding of cosmic structure.- Innovative Martian Construction: Discover how researchers at Texas A&M University are pioneering biomanufacturing methods to build structures on Mars using its natural resources. By mimicking the properties of lichens, scientists are developing a synthetic system that can bind Martian regolith into strong building materials, paving the way for sustainable human habitats on the Red Planet.- Charting the Cosmic Web: We discuss groundbreaking observations of a 23 million light-year-long gaseous filament and the role of fast radio bursts in mapping the universe's largest structures. Learn how these discoveries are reshaping our understanding of baryonic matter distribution within the cosmic web.For more cosmic updates, visit our website at astronomydaily.io. Join our community on social media by searching for #AstroDailyPod on Facebook, X, YouTube Music Music, TikTok, and our new Instagram account! Don't forget to subscribe to the podcast on Apple Podcasts, Spotify, iHeartRadio, or wherever you get your podcasts.Thank you for tuning in. This is Steve signing off. Until next time, keep looking up and stay curious about the wonders of our universe.✍️ Episode ReferencesPerseid Meteor Shower[NASA](https://www.nasa.gov/)Cosmic Void Research[Royal Astronomical Society](https://ras.ac.uk/)Martian Construction Matt Woods[Texas A&M University](https://www.tamu.edu/)Cosmic Web Observations[Harvard-Smithsonian Center for Astrophysics](https://www.cfa.harvard.edu/)Astronomy Daily[Astronomy Daily](http://www.astronomydaily.io/)Become a supporter of this podcast: https://www.spreaker.com/podcast/astronomy-daily-space-news-updates--5648921/support.

In this episode of The NREL Podcast, hosts Taylor Mankle and Kerrin Jeromin spotlight three stories where innovation meets real-world impact, including: Marine energy tech getting a surprising upgrade. NREL researchers test an elevator pulley belt to improve their wave-powered desalination device, called the HERO WEC. A major milestone for secure transportation data sharing. The Transportation Secure Data Center celebrates 15 years of enabling smarter transportation planning while protecting user privacy. How a new collaboration with Crysalis Biosciences is transforming shuttered chemical plants into cutting-edge biofuel and biochemical production hubs. This episode was hosted by Kerrin Jeromin and Taylor Mankle, written and produced by Allison Montroy, Hannah Halusker, and Kaitlyn Stottler, and edited by James Wilcox, Joe DelNero, and Brittany Falch. Graphics are by Brittnee Gayet. Our title music is written and performed by Ted Vaca and episode music by Chuck Kurnik, Jim Riley, and Mark Sanseverino of Drift BC. Transforming Energy: The NREL Podcast is created by the U.S. Department of Energy's National Renewable Energy Laboratory in Golden, Colorado. Email us at podcast@nrel.gov. Follow NREL on X, Instagram, LinkedIn, YouTube, Threads, and Facebook.

Global Market Insights predicts the precision fermentation market for food and beverage will grow from just about two billion in 2024 to 70 billion globally by 2034. That's a staggering combined annual growth rate of nearly 40%. Liberation Labs is pioneering a new approach to precision fermentation at scale that borrows a page from the pharmaceutical industries playbook. Co-founder and CEO, Mark Warner, joins us to get into: What exactly is precision fermentation? The challenge facing companies, particularly early-stage innovators, that Liberation Labs saw an opportunity to solve for with contract precision fermentation The company's recent announcement of its first customer for the Indiana facility, Vivici, what they will do for them and what's exciting about the partnership How Mark saw an opportunity in the pharmaceutical space that could be replicated in fermentation for agbioscience innovation Mark's journey to fundraise for Liberation Labs Reflecting on the decision to put their facility in Indiana for access to talent, corn and transportation The biggest opportunities for growth – not just for Liberation Labs – but for precision fermentation as an industry Biomanufacturing's importance to economic growth, but in urban and rural America What's ahead for Liberation Labs

Global Market Insights predicts the precision fermentation market for food and beverage will grow from just about two billion in 2024 to 70 billion globally by 2034. That's a staggering combined annual growth rate of nearly 40%. Liberation Labs is pioneering a new approach to precision fermentation at scale that borrows a page from the pharmaceutical industries playbook. Co-founder and CEO, Mark Warner, joins us to get into:  What exactly is precision fermentation? The challenge facing companies, particularly early-stage innovators, that Liberation Labs saw an opportunity to solve for with contract precision fermentation The company's recent announcement of its first customer for the Indiana facility, Vivici, what they will do for them and what's exciting about the partnership How Mark saw an opportunity in the pharmaceutical space that could be replicated in fermentation for agbioscience innovation Mark's journey to fundraise for Liberation Labs Reflecting on the decision to put their facility in Indiana for access to talent, corn and transportation The biggest opportunities for growth – not just for Liberation Labs – but for precision fermentation as an industry Biomanufacturing's importance to economic growth, but in urban and rural America What's ahead for Liberation Labs 

Seeking ways to combat Indiana's teacher shortage, Indiana University is wrapping up the first semester of a teacher apprenticeship program where six candidates are working full time while taking classes. And Liberation Labs in Richmond has found its first client for its biomanufacturing plant in Richmond.

Send us a textWhat if we could revolutionize biotechnology by slashing antibody production costs by 70%? In a world where traditional mammalian cell cultures struggle with scalability and cost-effectiveness, an unexpected hero emerges from the depths of our oceans - microalgae.The use of microalgae in biotechnology is not just a novelty but a necessity, given the current demands for more efficient and cost-effective production methods. Muriel Bardor, co-founder, CEO and CSO of Alga Biologics, highlights a particularly startling statistic: microalgae can reduce the cost of antibody production by an impressive 70%. This innovation could revolutionize the biotechnology industry by making life-saving therapies more accessible.Here are 3 key takeaways from this podcast episode:Quality and Safety Assurance: By collaborating with virology experts and using advanced techniques like mass spectrometry, they ensure that their processes are virus-free and free from host-cell protein contamination. The company is paving the way for future developments despite the challenges of not having standard ELISA kits commercially available.Regulation and Industry Perception: Launching such transformative technology inevitably entwines with regulatory landscapes. Muriel and her company have begun discussions with the French regulatory agency, drawing optimism from the fact that similar plant-based products, such as glucocerebrosidase, have already paved the way in the market. This indicates a growing acceptance within regulatory bodies of alternative bioprocessing platforms, inspiring hope for microalgae's future in antibody production.Future Vision: Muriel hopes to break conservative barriers within pharmaceutical companies and promote the adoption of microalgae production. This offers not only cost-effective solutions but also holds potential for new treatment options, like for neuroblastoma.Check out the episode to hear Muriel's advice for aspiring scientists and the general public alike regarding the future of research and the well-being of our planet.Connect with Muriel Bardor:LinkedIn: www.linkedin.com/in/muriel-bardor-47953024Email: muriel.bardor@univ-rouen.frAlga Biologics: www.algabiologics.comNext step:Book a free consultation to refine your CMC strategy to propel your success: https://bruehlmann-consulting.com/callDevelop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotech

Send us a textThe world of biologics manufacturing is about to be transformed by a breakthrough that slashes antibody production costs by 70%. This revolutionary approach leverages the untapped potential of microalgae to deliver a sustainable, cost-effective solution that could make life-saving therapeutics more accessible than ever before. Enter microalgae, the star of this groundbreaking development.In this episode of the Smart Biotech Scientist, Muriel Bardor, the co-founder, CEO and CSO of Alga Biologics, shared insights into how her team's pioneering work with microalgae could redefine the landscape of immunotherapy.Here are some takeaways from her conversation with David Brühlmann:Green Revolution in Bioprocessing: Discover how microalgae can slash production costs by 70% and offer a sustainable alternative to traditional antibody manufacturing. Muriel explains how these photosynthetic organisms capture 7 tons of CO2 per kilogram of product - transforming antibody manufacturing both economically and environmentally.Rethinking Antibody Production: Learn why the conventional use of mammalian cells in antibody production is being challenged and how microalgae overcome the limitations of traditional methods, bringing life-saving drugs within reach for more people globally.Sustainable Impact: With a process that mirrors nature, Muriel's approach sets a new standard for eco-friendly biotech production. Find out how microalgae are changing not just the industry, but our world.We invite you to listen to this insightful conversation and explore how you can apply these groundbreaking ideas to your own work. Has Muriel's innovative approach inspired you? Share your thoughts or questions with us - we'd love to hear from you!If you are interested in antibody production, here is another episode worth listening:Episodes 47-48: Mastering Process Economics: Driving Down Costs in Antibody Production with Brian KelleyConnect with Muriel Bardor:LinkedIn: www.linkedin.com/in/muriel-bardor-47953024Email: muriel.bardor@univ-rouen.frAlga Biologics: www.algabiologics.comNext step:Book a free consultation to refine your CMC strategy to propel your success: https://bruehlmann-consulting.com/callDevelop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotech

Biomanufacturing takes center stage in this week's podcast! My guest is Bert Verbruggen from imec. Bert and I explore the challenges of biomanufacturing and how inline production process monitoring can help solve these issues. Bert and I also discuss new inline sensor developments developed by imec  and the value that artificial intelligence can bring in these systems.

Send us a textIn the fast-evolving world of biotechnology, the pursuit of efficiency and faster development has never been more critical. The computational tools and models currently being integrated into bioprocessing present a groundbreaking approach that promises radical shifts in drug development timelines and capabilities.In the second part of our conversation, Yossi Quint, founder and CEO of Ark, shows us that the horizon of bioprocessing is lined with possibilities that could revolutionize biotherapeutics accessibility, cost, and speed in pharmaceutical innovations.Here are three key takeaways you don't want to miss:De-risking with Simulation: Yossi shared how simulation models can drastically reduce risks by running many scenarios before actual implementation. This approach optimizes processes, lowers costs, and speeds up the development cycle.Transfer Learning in Bioprocessing: Discover the potential of leveraging data across different types of molecules! Although challenging, the ultimate goal is to apply data learnings from one process to others, maximizing efficiency and success rates.Patient Impact & Cost Reduction: At the heart of these innovations is the goal of quicker, more affordable drug production. By slicing down on both time and costs, computational tools not only help drugs reach the market faster but also make them more accessible to patients globally.With innovation at its core, the modern trajectory of bioprocessing is not simply about reaching scientific milestones but about profoundly transforming patient care and accessibility. This synergistic blend of technology and purpose crafts a future in which the biotechnology sector not only grows but also enriches countless lives around the globe.If you are interested in this topic, here are a few standout conversations on AI's impact on bioprocessing with some incredible experts:Episodes 131-132: Combining AI and Biomanufacturing for Sustainable, Cost-Effective Therapeutics with Reza FarahaniEpisodes 115-116: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy AgrestiEpisodes 111-112: AI Meets Biology: Why Domain Expertise Still Rules in the Age of Large Language Models with Lars BrandénEpisodes 107-108: From 1 Billion to 100: How AI is Cracking the Enzyme Discovery Code with David SchönauerEpisodes 95-96: AI in Bioprocess Development: The Game-Changer You Can't Ignore with Belma AlispahicConnect with Yossi Quint:LinkedIn: https://www.linkedin.com/in/yossi-quintArk: https://www.ark-biotech.comNext step:Wondering how to develop biomanufacturing processes with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biotherapeutics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

Send us a textThe integration of AI into drug discovery has already led to groundbreaking advancements, uncovering patterns in vast datasets that were previously invisible to human researchers. Now, AI is set to revolutionize bioprocessing as well.In this episode of the Smart Biotech Scientist Podcast, Yossi Quint, founder and CEO of Ark, and David Brühlmann explore how AI and computational tools are reshaping bioprocess development. Yossi envisions a future where 90% of bioreactor experiments could be replaced by in silico simulations, dramatically accelerating time to market and increasing throughput.Key takeaways from the conversation with Yossi Quint:AI's Role in Drug Discovery & Bioprocessing: AI is already transforming drug discovery by identifying intricate patterns across millions of data points. Now, bioprocessing is undergoing a similar revolution, as computational tools simplify and streamline complex workflows.The Power of Hybrid Models: Yossi highlights the synergy between mechanistic models and AI-driven approaches, emphasizing how AI can fill gaps where traditional models struggle—especially in understanding complex cellular behaviors.Empowering Bioprocess Teams with AI: As AI accelerates drug discovery, bioprocessing must evolve to keep pace. Yossi discusses the importance of digital transformation in ensuring bioprocess teams can meet increasing demands and drive innovation forward.With AI-driven models, hybrid simulations, and increased digitization, the bioprocessing industry stands at the cusp of a new era. The convergence of data, science, and technology promises not only greater efficiency and accuracy but also a faster path to life-saving treatments for patients in need.If you want to learn more, here are a few standout conversations on AI's impact on bioprocessing with some incredible experts:Episodes 131-132: Combining AI and Biomanufacturing for Sustainable, Cost-Effective Therapeutics with Reza FarahaniEpisodes 115-116: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy AgrestiEpisodes 111-112: AI Meets Biology: Why Domain Expertise Still Rules in the Age of Large Language Models with Lars BrandénEpisodes 107-108: From 1 Billion to 100: How AI is Cracking the Enzyme Discovery Code with David SchönauerEpisodes 95-96: AI in Bioprocess Development: The Game-Changer You Can't Ignore with Belma AlispahicConnect with Yossi Quint:LinkedIn: https://www.linkedin.com/in/yossi-quintArk: https://www.ark-biotech.comNext step:Wondering how to develop biomanufacturing processes with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biotherapeutics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

Send us a textArtificial Intelligence (AI) is transforming industries worldwide, and biotechnology is no exception. In bioprocess development, AI is proving to be a game-changer, accelerating workflows, optimizing processes, and driving innovation. On the Smart Biotech Scientist Podcast, Reza Farahani, founder and CEO of Catalyze AI, shares his insights on how AI is reshaping biomanufacturing and the future of the industry.As AI continues to integrate into bioprocessing, the role of scientists is evolving. Farahani envisions a future where scientists collaborate with AI to enhance efficiency. One of Catalyze AI's exciting innovations is an agentic root cause analysis tool, designed to automate troubleshooting. Instead of spending hours on manual analysis, scientists will receive AI-generated reports outlining probable causes of failures—allowing them to focus on high-level decision-making.What you'll learn in this episode:Exciting Advances in AI: Farahani highlights the potential of Artificial General Intelligence (AGI)—AI that can generate ideas through analogy, much like humans do. Imagine an AI system recognizing a successful method in the petroleum industry and applying those principles to biomanufacturing. This kind of cross-disciplinary innovation could unlock groundbreaking efficiencies.Leadership Principles in AI-Driven Biotech Startups: Farahani takes an unconventional approach to leadership. Unlike corporate environments where avoiding mistakes is crucial, he encourages his team to embrace failure early on. "I want to see you make a mistake in the first month," he tells new hires. By removing the fear of failure, his team can experiment, think creatively, and drive true innovation—an essential mindset for biotech startups breaking new ground.Advice for Aspiring Biotech Entrepreneurs: Farahani's advice is simple: find a problem, develop a unique solution, and take action. He urges scientists to identify small inefficiencies that can be scaled and optimized. Equally important is being open to failure and iterating quickly to refine solutions. Success comes from starting, adapting, and continuously improving.As we stand on the brink of a biomanufacturing revolution, the real opportunity lies in combining AI with biologics. While AI often dominates the conversation, Farahani emphasizes that biologics remain underhyped. The true breakthroughs will come from leveraging AI to solve real-world challenges in biomanufacturing, leading to significant efficiencies and industry-wide advancements.For those passionate about this field, staying connected with thought leaders like Reza Farahani and keeping up with the latest innovations is key. As AI and biologics continue to converge, the future of bioprocessing holds unprecedented potential for transformation and progress.Curious about how AI is transforming bioprocessing? Discover how industry experts are driving innovation to shape the future of this field.Episodes 111 and 112: AI Meets Biology: Why Domain Expertise Still Rules in the Age of Large Language Models with Lars BrandénEpisodes 107 and 108: From 1 Billion to 100: How AI is Cracking the Enzyme Discovery Code with David SchönauerConnect with Reza FarahaniLinkedIn: https://www.linkedin.com/in/reza-farahani-/Catalyze AI: https://www.catalyzeai.com/Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biotherapeutics better, faster, at a fraction of the cost with our 1:1 Strategy Call.

Send us a textThe real-world applications of AI in biomanufacturing are transformative. From reducing drug development timelines to optimizing production yields, AI is making biomanufacturing more efficient and cost-effective. This, in turn, enhances global access to life-saving therapies. As AI continues to evolve, its potential to drive even greater innovations in biologics manufacturing becomes increasingly promising.In the latest episode of the Smart Biotech Scientist Podcast, David Brühlmann speaks with Reza Farahani, founder and CEO of Catalyze AI, about the profound impact of AI on biomanufacturing. They discuss how AI is reshaping drug development, reducing costs, and simplifying complex biomanufacturing processes - bringing us closer to a future where life-saving drugs are as accessible as smartphones.Why You Should Tune In:AI's Role in Democratizing Biomanufacturing: One of the core missions of Catalyze AI is to democratize the sophisticated knowledge that currently resides mostly within top pharmaceutical companies. By leveraging AI to improve bioprocess development, Farahani aims to bridge the knowledge gap between academia and industry, thereby reducing the cost and accelerating the development of new therapeutics. This democratization of bioprocess knowledge could potentially revolutionize the accessibility and affordability of life-saving drugs.How AI Optimizes Bioprocess Development: AI has the unique ability to manage and analyze complex, convoluted data sets much more efficiently than humans. Reza explains how transformer models—similar to the ones used in natural language processing tasks by ChatGPT—can be utilized to predict and optimize various steps in the biomanufacturing process. These models can learn and make predictions based on past data, enabling a significant reduction in the time and resources required for process development.Solving the Scale-Up Challenge: Scale-up remains one of the most challenging aspects of bioprocess development, often plagued by delays and inefficiencies. AI can immensely help by leveraging data from both small and large-scale biomanufacturing processes to predict optimal conditions. However, given the complexity and high cost associated with scale-up experiments, Reza envisions a future where distributed, small-scale biomanufacturing units could replace large-scale facilities. This would not only reduce costs but also enhance flexibility and resilience against process failures.AI is not just accelerating drug development—it's reshaping the entire biomanufacturing landscape. Don't miss this insightful conversation on how AI is driving the future of biotech.As we stand at the intersection of AI and biomanufacturing, the possibilities are limitless. With continued advancements, we may soon witness a paradigm shift where drug production becomes more decentralized, efficient, and tailored to global healthcare needs. The future of biotech is being written now—are you ready to be part of it?Interested in exploring more about AI's impact on bioprocessing? Check out what other experts in the field are doing to drive innovation in this space.Episodes 119 and 120: Innovating Protein Purification Using Synthetic Organelles and AI with Haotian GuoEpisodes 115 and 116: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy AgrestiConnect with Reza FarahaniLinkedIn: https://www.linkedin.com/in/reza-farahani-/Catalyze AI: https://www.catalyzeai.com/Wondering how to develop biomanufacturing processes with peace of mind? Schedule your free assessment to propel your success:

Doug Friedman joins the podcast to talk about one of the toughest challenges in biotech—how to survive long enough to actually make an impact. As the head of BioMADE, he's on a mission to build a bioindustrial manufacturing ecosystem that doesn't just rely on wishful thinking and a single grant check. He explains why most biotech startups get only "one shot on goal" (spoiler: they miss, they're done) and how we can fix that. Think of it like debugging a bad DNA sequence—you need iteration, not instant perfection. Doug also discusses how government funding is shaping the future of biomanufacturing, why biology today is where semiconductors were in the ‘80s, and why scaling biology might just need its own version of Moore's Law. Grow Everything brings the bioeconomy to life. Hosts Karl Schmieder and Erum Azeez Khan share stories and interview the leaders and influencers changing the world by growing everything. Biology is the oldest technology. And it can be engineered. What are we growing? Learn more at www.messaginglab.com/groweverything  Chapters: 00:00:00 – Fail Fast or Fail Forever – Why biotech startups need more than one shot on goal 00:00:27 – AI Shake-Up – DeepSeek changes the game (and the stock market) overnight 00:01:01 – China vs. AI – What a hedge fund, government crackdowns, and new algorithms have in common 00:02:19 – Power Hungry AI – Why data centers might outgrow the energy grid before we're ready 00:03:36 – DeepSeek's Disruption – What it means for AI, efficiency, and the future of computing 00:04:13 – Innovation Under Pressure – How limitations create the best breakthroughs 00:05:46 – Mind Reading? – The wild world of telepathy research and what it means for biotech 00:07:45 – Quantum Strangeness – Exploring dimensions beyond what we can see 00:09:17 – Longevity Hacks – The Brian Johnson experiment: biohacking or billion-dollar placebo? 00:12:48 – Biomanufacturing is Booming – Why the future of production is biological 00:28:35 – PFAS Panic – 3M halts production, and microelectronics scrambles for solutions 00:30:53 – BioMADE's Master Plan – How industry collaboration is making biomanufacturing real 00:36:56 – Government Meets Biotech – Bridging public and private sectors for impact 00:38:44 – The Bioeconomy is Here – What it means for industries beyond biotech 0:42:29 – Talk to Your Legislators – How to get policymakers to care about biotech 00:46:08 – The Hardest Part of Biomanufacturing – What innovators need to overcome 00:50:42 – Biomanufacturing's Future – The biggest opportunities waiting to be unlocked 00:52:46 – Final Thoughts – Wrapping up lessons from the frontier of biotech Links and Resources: BioMADE Homeworld Collective (Apply today!) The Climate Biotech Podcast DeepSeek Wipes $1 Trillion from Tech Share Prices The Telepathy Tapes Don't Die, The Man Who Wants to Live Forever Rapamycin General Probiotics Antheia Schmidt Sciences Liberation Labs Topics Covered:  biomanufacturing, collaboration, public private partnerships, distributed biomanufacturing, longevity biotech, telepathy, tech  Have a question or comment? Message us here: Text or Call (804) 505-5553  Instagram  / Twitter / LinkedIn / Youtube / Grow Everything Email: groweverything@messaginglab.com Music by: Nihilore Production by: Amplafy Media

Noah Helman, co-founder of Industrial Microbes, unpacks how his team is giving ethanol a glow-up as a renewable feedstock for creating advanced polymers and sustainable carbon fibers. With a decade of experience in the trenches of biomanufacturing, Noah discusses how they're engineering microbes to work smarter, not harder, tackling the challenges of cost, scale, and environmental impact. From leveraging industrial partnerships to envisioning a future where waste becomes the ultimate raw material, Noah delivers sharp insights with a side of microbial magic, proving that biology is not just life—it's a powerhouse of innovation. Grow Everything brings the bioeconomy to life. Hosts Karl Schmieder and Erum Azeez Khan share stories and interview the leaders and influencers changing the world by growing everything. Biology is the oldest technology. And it can be engineered. What are we growing? Learn more at ⁠⁠⁠⁠⁠www.messaginglab.com/groweverything⁠⁠⁠⁠⁠ Chapters: 00:00:00 - Prelude to Progress: The Challenge of Unique Equipment 00:00:21 - Oil, Politics, and the Biomanufacturing Tug-of-War 00:01:58 - From Biofuel Bust to Synthetic Biology Boom 00:03:59 - A Pledge Against Plastics: Aquarium Insights 00:05:35 - Woolly Mammoths and Capitalist Dinosaurs 00:08:11 - TikTok Drama: Perplexity's Unlikely Bid 00:12:29 - Ethanol: From Gas Tank to Biomanufacturing Hero 00:15:00 - Meet Noah Helman: Biomanufacturing Pioneer 00:18:00 - Scaling Up: The Chicken-and-Egg of Biomanufacturing 00:22:45 - Breaking Bottlenecks: Innovations in Equipment Access 00:27:00 - Collaborating for Carbon Fiber: Partnerships in Progress 00:30:27 - Spinning Carbon: Fiber Meets Sustainability 00:34:28 - Cracking the Code of Biomanufacturing Bottlenecks 00:36:51 - Waste Not, Want Not: The Power of Circular Inputs 00:42:34 - Futurecasting Biomanufacturing and Bioeconomies 00:45:03 - Next-Gen Biology: Enzymes, AI, and Big Data 00:50:58 - Closing the Loop: Microbial Magic and Future Frontiers Episode Links: iMicrobes The ROI of Waste  Beyond Petrochemicals BioMADE ARPA-E  First Bight Ventures Biowell  (accelerator program) Colossal biosciences raises $200M at 10B valuation Perplexity bids for TikTok  Arc Institute partners with NVIDIA to accelerate computational biomedical research Topics Covered: Biomanufacturing, acrylic acid, acrylonitrile, carbon nanofibers, industrial microbes, biotech startups, spaceships, accelerators, synbio investments  Have a question or comment? Message us here: Text or Call (804) 505-5553 ⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠  / ⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠Youtube⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠Grow Everything⁠⁠⁠⁠⁠ Email: groweverything@messaginglab.com Music by: Nihilore Production by: Amplafy Media

NINA TANDON Nina Tandon is a remarkable person, who is currently Co-Founder and CEO of EpiBone, a biotech company that grows bone and cartilage for skeletal reconstruction which just recently completed human trials reconstructing mandibles; the lower jaw is the largest and strongest bone in the face. Her life and accomplishments are inspiring and is deeply thoughtful, multi-dimensional and extremely driven. A great episode to kick off 2025, Happy New Year to all! She grew up on Roosevelt Island on the East River in New York City, and showed interest in science as a child when, her siblings suffered from eye conditions. They were encouraged to try various science experiments: Nina took apart TVs, built giant Tinkertoy towers, played with static solved complex puzzles, and dabbled in community theatre, poetry, and sewing. She studied French, Hindi and Italian, runs marathons, and enjoys metal-smithing and being a yoga instructor. EpiBone has raised millions in investor funding and has received such distinctions as the World Economic Forum's 2015 Technology Pioneer, named one of the 100 most exciting start-ups in New York City by Business Insider. Nina has been recognized as one of the 100 Most Creative People in Business by Fast Company Magazine; an Ernst & Young Winning Women and Goldman Sachs' 100 Most Intriguing Entrepreneurs, among others. Nina started her career as an electrical engineer. Then while studying abroad on a Fulbright scholarship, she worked on an electronic nose to “smell” lung cancer. This ignited her passion for healthcare and changed the course of her career. She went back to school, earning a master's in bioelectrical engineering from Massachusetts Institute of Technology (MIT), and two advanced degrees from Columbia University – an MBA in healthcare entrepreneurship and a PhD in Biomedical Engineering. With decades of experience as both a scientist and entrepreneur, Nina is a loud voice that raises  awareness on  the field of tissue engineering. She has done a number of TED Talks, has published in Forbes magazine, and was featured on the Netflix series “Human: The World Within". In 2022, she offered  policy perspectives at the White House Summit on Biotechnology and Biomanufacturing. RELATED LINKS Epibone Wikipedia Columbia Board Visitor TED Talks Crain's Women in Health GENERAL INFO| TOP OF THE GAME: Official website: https://topofthegame-thepod.com/ RSS Feed: https://feed.podbean.com/topofthegame-thepod/feed.xml Hosting service show website: https://topofthegame-thepod.podbean.com/ Javier's LinkTree: https://linktr.ee/javiersaade  SUPPORT & CONNECT: LinkedIn: https://www.linkedin.com/showcase/96934564 Facebook: https://www.facebook.com/profile.php?id=61551086203755 Twitter: https://twitter.com/TOPOFGAMEpod Subscribe on Podbean: https://www.podbean.com/site/podcatcher/index/blog/vLKLE1SKjf6G Email us: info@topofthegame-thepod.com   THANK YOU FOR LISTENING – AVAILABLE ON ALL MAJOR PLATFORMS